Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

BACKGROUND: Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC). Although the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pulm Med
Main Authors: Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Yamakawa, Hideaki, Morita, Masato, Kitamura, Hideya, Ogura, Takashi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778330/
https://ncbi.nlm.nih.gov/pubmed/26940352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-016-0201-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados